These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460 [TBL] [Abstract][Full Text] [Related]
4. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Benešová M; Umbricht CA; Schibli R; Müller C Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475 [TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Characterization of an Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329 [TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors. Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351 [TBL] [Abstract][Full Text] [Related]
9. Enhancing Treatment Efficacy of Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544 [TBL] [Abstract][Full Text] [Related]
10. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996 [TBL] [Abstract][Full Text] [Related]
11. Effects of Linker Modification on Tumor-to-Kidney Contrast of Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108 [No Abstract] [Full Text] [Related]
12. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer. Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647 [TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845 [TBL] [Abstract][Full Text] [Related]
14. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy. Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947 [TBL] [Abstract][Full Text] [Related]
15. PSMA-targeted combination brusatol and docetaxel nanotherapeutics for the treatment of prostate cancer. Adekiya TA; Hudson T; Bakare O; Ameyaw EE; Adebayo A; Olajubutu O; Adesina SK Biomed Pharmacother; 2024 Aug; 177():117125. PubMed ID: 39002444 [TBL] [Abstract][Full Text] [Related]
16. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698 [TBL] [Abstract][Full Text] [Related]
17. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy. Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114 [TBL] [Abstract][Full Text] [Related]
18. Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation. Lesniak WG; Boinapally S; Lofland G; Jiang Z; Foss CA; Behman Azad B; Jablonska A; Garcia MA; Brzezinski M; Pomper MG Int J Nanomedicine; 2024; 19():4995-5010. PubMed ID: 38832336 [TBL] [Abstract][Full Text] [Related]